At the news
? NEUTRALIMPACT 5/10 8-K filed Nov 13, 2026 at 07:36 ET
Milestone Pharmaceuticals reported Q3 2026 product revenue of $1.0M, up 73% QoQ, and announced a 30% operating expense reduction to extend cash runway into late 2028, beyond the expected Phase 3 AFib-RVR data readout in 2H 2028. The CFO and CMO have departed, and the company amended its convertible notes to extend the PIK interest period to March 2029.
- Q3 2026 product revenue $1.0M, up 73% from Q2 2026 ($0.6M)
- Operating expenses to be reduced by approximately 30%
- Cash and equivalents $145.4M as of Sep 30, 2026; runway extended into late 2028
- CFO Amit Hasija and CMO David Bharucha have departed; Anthony Krick named Principal Financial Officer
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access